Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027

Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027

Parabilis Medicines (NASDAQ:PBLS) presented updated interim phase I/II data for investigational beta-catenin/TCF inhibitor zolucatetide in desmoid tumors at the European Society for Medical Oncology Congress in Madrid, reporting tumor responses, disease control and an FDA-aligned plan for a registra

Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors

Objective response rate of 72.2% among response-evaluable patients receiving a starting dose of ≥450 mg at 32-week landmarkDisease control rate of 100%...